Kestra Medical Technologies, Ltd. KMTS
27.14
1.38
5.36%
as of 25 Sep
- Market cap
- $1.5B
- P/E
- 0.0×
Follow KMTS
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
P/E ratio |
+6 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
18.94 | 16.68 | 11.80 | 12.53 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(76.69) | (76.02) | (59.97) | (41.40) | |
P/B ratio |
8.57 | 4.85 | 4.32 | 6.01 | |
Price to Tangible BV |
8.57 | 4.85 | 4.32 | 6.01 | |
EV/Sales |
17.14 | 13.70 | 10.19 | 11.34 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.69) | (13.18) | (11.86) | (13.80) | |
EV/FCF |
(11.15) | (9.56) | (8.29) | (9.84) | |
Quick Ratio |
5.20 | 7.08 | 4.19 | 4.44 | |
Current Ratio |
5.47 | 7.32 | 4.41 | 4.69 | |
Net Debt/EBITDA |
4.62 | 7.71 | 4.20 | 3.56 | |
Debt/Assets |
16.97% | 11.14% | 11.90% | 20.87% | |
Debt/Equity |
0.26 | 0.15 | 0.16 | 0.33 | |
Asset Turnover |
0.60 | 0.44 | 0.29 | 0.35 | |
Operating CF/Net income |
0.56 | 0.54 | 0.48 | 0.73 | |
Capex/Depreciation |
(2.61) | (4.05) | (3.60) | (3.82) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
21.62% | 20.25% | 19.67% | 21.94% | |
Selling, General and Administrative Expense of Revenue |
169.74% | 173.91% | 172.47% | 156.14% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
38.35% | 41.17% | 35.98% | 30.73% | |
Graham Net Nets |
0.08 | 0.16 | 0.11 | 0.08 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(16.23%) | (15.84%) | (11.68%) | (11.71%) | |
Free Cash Flow Yield |
(8.12%) | (8.60%) | (10.42%) | (9.20%) | |
Revenue per Share |
0.44 | 0.44 | 0.53 | 0.53 | |
Operating CF per Share |
(0.36) | (0.33) | (0.35) | (0.55) | |
Capex per Share |
(0.14) | (0.18) | (0.18) | (0.14) | |
Free Cash Flow per Share |
(0.50) | (0.51) | (0.52) | (0.69) | |
Cash per Share |
3.41 | 5.22 | 3.63 | 3.40 | |
Shareholders Equity per Share |
3.19 | 5.16 | 4.79 | 3.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.19 | 5.16 | 4.79 | 3.80 | |
Free Cash Flow |
(25.76) | (28.28) | (28.38) | (40.63) | |
Working Capital |
159.66 | 271.13 | 171.99 | 178.00 | |
Capital Expenditures |
(7.42) | (9.92) | (9.66) | (8.33) | |
Net Current Asset Value |
112.79 | 222.71 | 123.55 | 101.28 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.33 | 0.40 | 0.34 | 0.27 | |
Net Profit Margin |
(145.29%) | (139.16%) | (135.61%) | (142.35%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 7.35 | 11.31 | 12.33 | |
Average Payables |
— | 23.96 | 25.63 | 22.27 | |
Average Assets |
123.35 | 189.67 | 327.10 | 306.83 | |
Average Common Equity |
— | 39.31 | 232.53 | 203.26 |
Columns are period end dates